Pay in 4 interest-free payments of $5.55 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
We do not provide dosage, administration, injection, or usage guidance, in line with our policy
Phase 3 side effect profiles are expected to be similar
HGF/c-Met signaling is a well-established oncogenic pathway: c-Met is amplified or overexpressed in multiple cancers (gastric, lung, renal, hepatocellular) HGF/c-Met activation promotes tumor cell proliferation, survival, invasion, and metastasis c-Met inhibitors are FDA-approved cancer drugs (cabozantinib, crizotinib, capmatinib) A compound that potentiates HGF/c-Met signaling raises theoretical concerns about promoting tumor growth or transformation with chronic use
One evaluation, one provider, bundle pricing
The present experiments describe the effects of nitric oxide (NO) agonists and antagonists and the influence of NaBPC157 on the development of Pulmonary Hypertension Syndrome (PHS) and tissue lesions in chicks
US$ 21.39
US$ 27.97
US$ 27.81
